Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (61-70 of 215) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|October 30, 2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasiaAmer M Zeidan, B Douglas Smith, Hetty E Carraway, et al.
Haematologica|November 22, 2011
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromesSheila Weiss Smith, Masayo Sato, Steven D Gore, et al.
Leukemia & Lymphoma|July 26, 2017
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromesKatharine R Press, Natalie Uy, Jeffrey Keefer, et al.
Cancer|August 1, 2017
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trialsAmer M Zeidan, Maximilian Stahl, Mikkael A Sekeres, et al.
Journal of Medicinal Chemistry|September 30, 2005
Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitorsSheeba Varghese, Deepak Gupta, Tiffany Baran, et al.
Leukemia Research|March 26, 2013
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelinesAmy J Davidoff, Sheila R Weiss, Maria R Baer, et al.
Leukemia Research|February 10, 2020
Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemiaRory M Shallis, Timil H Patel, Nikolai A Podoltsev, et al.
Blood Cancer Discovery|November 15, 2021
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic MalignanciesAntoni Ribas, Madhav V Dhodapkar, Katie M Campbell, et al.
Biomedical Chromatography : BMC|November 30, 2021
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclaxSusan C Scott, Nicole M Anders, Ping He, et al.
Annals of Hematology|October 23, 2021
Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapyRory M Shallis, Darko Pucar, Sudhir Perincheri, et al.
Pageof 22

Showing results (61-70 of 215) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|October 30, 2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasiaAmer M Zeidan, B Douglas Smith, Hetty E Carraway, et al.
Haematologica|November 22, 2011
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromesSheila Weiss Smith, Masayo Sato, Steven D Gore, et al.
Leukemia & Lymphoma|July 26, 2017
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromesKatharine R Press, Natalie Uy, Jeffrey Keefer, et al.
Cancer|August 1, 2017
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trialsAmer M Zeidan, Maximilian Stahl, Mikkael A Sekeres, et al.
Journal of Medicinal Chemistry|September 30, 2005
Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitorsSheeba Varghese, Deepak Gupta, Tiffany Baran, et al.
Leukemia Research|March 26, 2013
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelinesAmy J Davidoff, Sheila R Weiss, Maria R Baer, et al.
Leukemia Research|February 10, 2020
Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemiaRory M Shallis, Timil H Patel, Nikolai A Podoltsev, et al.
Blood Cancer Discovery|November 15, 2021
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic MalignanciesAntoni Ribas, Madhav V Dhodapkar, Katie M Campbell, et al.
Biomedical Chromatography : BMC|November 30, 2021
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclaxSusan C Scott, Nicole M Anders, Ping He, et al.
Annals of Hematology|October 23, 2021
Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapyRory M Shallis, Darko Pucar, Sudhir Perincheri, et al.
Pageof 22